Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 27.500917
debtToEquity 1.343000
earningsGrowth 0.046000
revenueGrowth 0.138000
grossMargins 0.760520
operatingMargins 0.257330
trailingEps 74.340000
forwardEps 99.280000

Ajanta Pharma Limited's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
With positive gross and operating margins, AJANTPHARM demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
Ajanta Pharma Limited's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with Ajanta Pharma Limited anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Ajanta Pharma Limited's price has frequently been situated near the lower end of analysts' projections. This trend indicates that the stock is struggling to meet expectations, which could signal a need for improvements in performance or investor confidence.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


12 Ajanta Pharma Limited transactions were recorded, when the market price was 2972.9749959309897.There were no sell transactions during the given timeframe.AJANTPHARM is seeing more buys than sells at current price levels, which may indicate a positive market outlook. This trend suggests growing confidence among investors, who appear to expect favorable performance from the stock.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts have shown a buy bias for Ajanta Pharma Limited, marking it as a favorable investment option. This could inspire investors to see Ajanta Pharma Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.